Pramiracetam
Dosage
Oral bands as drawn from PsychonautWiki's ranges below. The table is the source of truth.
When sources disagree, both rows are shown as published. Nothing is averaged or merged.
Oral
| Source | Threshold | Light | Common | Strong | Heavy |
|---|---|---|---|---|---|
| PsychonautWiki | 100 mg PW | 250–500 mg PW | 500–800 mg PW | 800–1200 mg PW | 1200 mg+ PW |
| TripSit | – | – | 400–1200 mg TS | – | – |
Note: Usually taken two or three times a day. So 400mg taken three times a day. Or 600mg three times a day. TS
TripSit dose text
TripSit's factsheet also states its doses as text.
Common: 400-1200mg | Note: Usually taken two or three times a day. So 400mg taken three times a day. Or 600mg three times a day. TS
What dose are you on? (self-reported, unverified)
No reports yet.
Reports are anonymous, one per browser per day per route. Counts under 20 are shown but marked as too few to mean anything. Until accounts launch, reports stay in this browser only.
Duration
| Route · source | Onset | Come-up | Peak | Offset | Total | After-effects |
|---|---|---|---|---|---|---|
| Oral · PsychonautWiki | 30–90 minutes PW | – | – | – | 4–7 hours PW | – |
TripSit factsheet
Mixing
Acute combinations: what happens when these are taken close together. Entries backed by a medical journal or agency are listed first.
Backed by medical journals
Risks and toxicity
The toxicity and long-term health effects of pramiracetam use do not seem to have been studied in any scientific context and the exact toxic dosage is unknown. This is because pramiracetam has very little history of human usage. Anecdotal evidence from people who have tried pramiracetam within the community suggest that there do not seem to be any negative health effects attributed to simply trying this drug at low to moderate doses by itself and using it sparingly (but nothing can be completely guaranteed). PW
There are anecdotal reports of users experiencing painful chemical burns caused by ingesting pramiracetam powder sublingually. Other routes of administration do not seem to cause the same effects. PW
It is strongly recommended that one use harm reduction practices when using this substance. PW
Dependence and abuse potential
The chronic use of Pramiracetam can be considered as not addictive with a low potential for abuse. It does not seem to be capable of causing psychological dependence among certain users. PW
Tolerance to many of the effects of Pramiracetam develops with prolonged and repeated use. This results in users having to administer increasingly large doses to achieve the same effects. After that, it takes about 3 - 7 days for the tolerance to be reduced to half and 1 - 2 weeks to be back at baseline (in the absence of further consumption). Pramiracetam may presents cross-tolerance with all racetam nootropics, meaning that after the consumption of pramiracetam certain nootropics such as aniracetam and piracetam may have a reduced effect. PW
Testing
Effects
Overview
Pramiracetam (also known as Pramistar) is a nootropic stimulant of the racetam class. It is a derivative of piracetam, which has been studied as a cognitive enhancing agent. PW
A CNS stimulant that is a nootropic, that belongs to the racetam family of compounds. Much more potent than Piracetam while appearing to work on similar mechanisms. TS
Pramiracetam is a nootropic agent belonging to the racetam family of drugs. It is marketed by Menarini under the brand name Pramistar as a treatment for memory and attention deficits in aging people with neurodegenerative and vascular dementias in Italy and some Eastern European countries.[1]
Pramiracetam was discovered by scientists at Parke-Davis, at that time a division of Warner-Lambert, in the late 1970s; patents expired in 1996. Warner-Lambert conducted clinical trials in Alzheimer's Disease and abandoned that indication after Phase II trials showed mixed results; it then began to develop it as an orphan drug as an adjunct to electroconvulsive therapy for major depressive disorder, in part to take advantage of the administrative exclusivity provided by the orphan status. It licensed European rights to Menarini which continued developing it for dementias, and in 1991 it licensed US and other non-European rights to Cambridge Neuroscience, Inc, (CNI) which pursued the ECT indication, as well as a use in restoring cognitive function after stroke or traumatic brain injury. CNI obtained the orphan designation for the ECT use from the FDA in 1991, which was later withdrawn when CNI abandoned the drug.[4]
CNI conducted a clinical trial in four people who had cognitive problems following a head injury. Trials conducted by or on behalf of Menarini and Warner-Lambert included two small trials conducted in Ukraine, one in people with cerebrovascular disease and another in people with concussion. Another small trial was performed in Italy, on healthy people in whom amnesia was induced with scopolamine.[6] WP
History
Legal status
Pharmacology
Chemistry
User reports
Erowid erowid.org
ListingsBluelight bluelight.org
ListingsReddit reddit.com
ListingsPop culture
No references added yet.
Add a reference
Registered users can add songs, films, books, shows, games and art about this substance. Link a source that names the substance, such as the work's Wikipedia article, a review or an interview, not only the work itself. Entries are voted on and moderated like every other value on this page.
Opens when accounts launch.
References
- Other AIFA Pramistar authorizations in the Agenzia Italiana del Farmaco Database Page accessed August 2, 2015. Italian Label, linked from that site]. link 2
- Other Drugs.com Drugs.com International listings for pramiracetam Page accessed August 2, 2015
- Other Italian marketing authorization for the brand name Remen has been revoked per the AIFA database, as has the marketing authorization for the brand name Neupramir, per the AIFA database, each checked on August 2, 2015. Main page at AIFA for pramiracetam is here. link 2 · link 3
- Other Staff, The Pink Sheet. May 27, 1991 Cambridge Neuroscience Developing Warner-Lambert's Pramiracetam
- Journal / agency FDA Orphan Drug Designations and Approvals Database Page accessed August 2, 2015
- Journal / agency Malykh AG, Sadaie MR. Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders. Drugs. February 2010. doi:10.2165/11319230-000000000-00000 · PMID 20166767
Text and values on this page are quoted from PsychonautWiki (CC BY-SA 4.0), Wikipedia (CC BY-SA 4.0), TripSit factsheets, PubChem (public domain). Each value links to the exact revision it came from.